Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Block listing Interim Review

1 Oct 2018 14:57

RNS Number : 5737C
Vernalis PLC
01 October 2018
 

BLOCK LISTING SIX MONTHLY RETURN AND BLOCK LISTING APPLICATION

 

VERNALIS PLC (the "Company")

 

1 October 2018

 

Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 

Name of applicant:

Vernalis plc

Name of scheme(s):

2007 Long Term Incentive Scheme ("LTIP"); 2012 Value Builder Plan ("VBP"); and

2016 Executive Incentive Plan ("EIP")

Period of return (from / to):

From: 29/Mar/2018

To: 01/Oct/2018

Balance of unallotted securities under scheme(s) from previous return:

Total of 2,149,159 Ordinary 1p Shares, split:

· Under LTIP = 360,485 Ordinary 1p Shares

· Under VBP = 1,788,674 Ordinary 1p Shares

· Under EIP = nil Ordinary 1p Shares

Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period:

Total of 166,376 Ordinary 1p Shares, split:

· Under LTIP = 39,405 Ordinary 1p Shares

· Under VBP = 126,971 Ordinary 1p Shares

Less: Number of securities forfeited under scheme(s) during period:

Total of 30,526 Ordinary 1p Shares:

· Under LTIP = 30,526 Ordinary 1p Shares

· Under VBP = nil Ordinary 1p Shares

· Under EIP = nil Ordinary 1p Shares

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

Total of 1,952,257 Ordinary 1p Shares, split:

· Under LTIP = 290,554 Ordinary 1p Shares

· Under VBP = 1,661,703 Ordinary 1p Shares

· Under EIP = nil Ordinary 1p Shares

Number and class of securities originally admitted and the date of admission (including any additions):

No. of Ordinary 1p Shares

Date on which Shares were Admitted to Trading

350,000

6 November 2013, plus

1,049,317

12 May 2014, plus

1,058,184

12 May 2015, plus

1,638,364

30 September 2015, plus

1,189,296

1 April 2016, plus

499,612

31 March 2017, plus

1,788,674

2 October 2017, plus

95,654

5 April 2018

 

-- ends --

 

Enquiries:

 

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer

 

Canaccord plc (Nominated Adviser and Broker):

+44 (0) 20 7523 8000

Henry Fitzgerald-O'Connor

Emma Gabriel

 

Evercore (Financial Adviser):

+44 (0) 20 7653 6000

Julian Oakley

Alan Beirne

 

 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, pharmaceutical company with significant expertise in drug development. The Group has two approved products: Moxatag®, a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. Vernalis has also nine programmes in its NCE development pipeline in addition to significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis and Servier.

 

For further information about Vernalis, please visit www.vernalis.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRMBBJTMBAMBJP
Date   Source Headline
28th Apr 20177:00 amRNSTotal Voting Rights
26th Apr 20177:00 amRNSServier and Vernalis announce 3 milestones
21st Apr 20177:01 amRNSVernalis receives $2 million milestone payment
21st Apr 20177:00 amRNSFDA Issues Complete Response Letter on CCP-07 NDA
29th Mar 20179:00 amRNSBlock listing Interim Review
6th Mar 20177:00 amRNSNew drug discovery collaboration with Servier
28th Feb 20177:00 amRNSTotal Voting Rights
21st Feb 20177:00 amRNSUnaudited interim results for 6 months to 31/12/16
14th Feb 20177:00 amRNSAchievement of a $3m milestone payment from Corvus
30th Jan 201712:36 pmRNSNotice of Results for Six Months Ended 31/12/2016
21st Dec 20167:00 amRNSFDA accepts CCP-08 NDA for full review
1st Dec 20161:00 pmRNSVernalis Results of Annual General Meeting
1st Dec 20167:00 amRNSAGM Statement
3rd Nov 20164:36 pmRNSHolding(s) in Company
31st Oct 20167:00 amRNSTotal Voting Rights
24th Oct 20169:43 amRNSNotice of Annual Report and AGM
13th Oct 201611:58 amRNSHolding(s) in Company
12th Oct 20164:58 pmRNSDirector/PDMR Shareholding
12th Oct 20164:57 pmRNSDirector/PDMR Shareholding
5th Oct 20162:00 pmRNSHolding(s) in Company
5th Oct 20161:02 pmRNSHolding(s) in Company
30th Sep 20163:55 pmRNSDirector/PDMR Shareholding
29th Sep 20163:00 pmRNSBlock listing Interim Review
29th Sep 20167:00 amRNSResults Announcement for 12 months ended 30/06/16
22nd Sep 20161:43 pmRNSHolding(s) in Company
14th Sep 201610:54 amRNSHolding(s) in Company
13th Sep 201610:34 amRNSNotice of Results
6th Sep 20167:00 amRNSFDA accepts CCP-07 NDA for full review
29th Jul 20167:00 amRNSTotal Voting Rights
26th Jul 201612:53 pmRNSHolding(s) in Company
19th Jul 20167:00 amRNSVernalis Achieves Oncology Milestone with Servier
15th Jul 20167:00 amRNSVernalis Notes RedoxTherapies Acquisition by Juno
8th Jul 20167:00 amRNSVernalis Announce CCP-08 Multiple-Dose Results
7th Jul 20161:47 pmRNSYear-end Trading Update and Notice of Results
30th Jun 20167:00 amRNSTotal Voting Rights
24th Jun 20163:52 pmRNSHolding(s) in Company
9th Jun 20162:58 pmRNSDirector Dealing
31st May 20167:00 amRNSTotal Voting Rights
19th May 20164:11 pmRNSMoxatag Supply Update
16th May 20162:44 pmRNSHolding(s) in Company
12th May 201611:10 amRNSResults of General Meeting
29th Apr 20167:00 amRNSTotal Voting Rights
27th Apr 20164:40 pmRNSHolding(s) in Company
26th Apr 20165:17 pmRNSPosting of Circular and Notice of General Meeting
26th Apr 201611:00 amRNSVernalis plc to raise £40 million in Placing
21st Apr 20162:26 pmRNSSandford Sommer appointed as President & COO in US
14th Apr 20167:00 amRNSVernalis Announce CCP-07 Multiple-Dose Results
13th Apr 20167:00 amRNSVernalis Announce CCP-08 Single-Dose Study Results
31st Mar 20169:00 amRNSTotal Voting Rights
29th Mar 20161:55 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.